International Clinical Trial: A Phase Ia, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SQ-23101 Injection in Patients with Thyroid Eye Disease

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133597) titled 'A Phase Ia, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SQ-23101 Injection in Patients with Thyroid Eye Disease' on Sept. 29.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Ninth Peoples Hospital,Shanghai JiaoTong University School of Medicine

Condition: Thyroid Eye Disease (TED)

Intervention: comparator drug-180 mg group:SQ-23101 Injection (blank) comparator drug-120 mg group:SQ-23101 Injection (blank) Investigational drug-30 mg group:SQ-2...